Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

3-Aminophthalic acid, a new cereblon ligand for targeted protein degradation by O’PROTAC
Yan, Yuqian , Shao, Jingwei , Ding, Donglin , Pan, Yunqian , Tran, Phuc , Li, Hongyu , Huang, Haojie , Huang, Rui , Yan, Wei , Wang, Zhenyu

Mayo Clinic

Chemical Communications | January 26, 2022 | Volume: 58 | Issue: 14 | Pages: 2383-2386

10.1039/d1cc06525d | PMID 35080528 Get It

In this study, we discovered 3-aminophthalic acid as a new ligand of cereblon (CRBN) E3 ubiquitin ligase and developed a phthalic acid-based O’PROTAC for ERG destruction, expanding the pool of ligands for development of PROTACs, especially O’PROTACs.
INTRIGUE: A phase III, randomized, open-label study to evaluate the efficacy and safety of ripretinib versus sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib
Schöffski, Patrick , Razak, Albiruni Ryan Abdul, Attia, Steven , Cesne, Axel Le, Su, Ying , Meade, Julie Nicole, Wang, Tao , Sherman, Matthew L. , Ruiz‐Soto, Rodrigo , Heinrich, Michael C. , Jones, Robin L. , Gelderblom, Hans , George, Suzanne , Mehren, Margaret von , Zalcberg, John , Kang, Yoon‐Koo , Trent, Jonathan C. , Blay, Jean‐Yves , Bauer, Sebastian

Mayo Clinic

Journal of Clinical Oncology | January 25, 2022 | Volume: 40 | Issue: 36_suppl | Pages: 359881-359881

10.1200/jco.2022.40.36_suppl.359881 Get It

359881 Background: Sunitinib is approved for advanced gastrointestinal stromal tumor (GIST) after imatinib failure. Ripretinib, a broad-spectrum KIT and PDGFRA switch-control tyrosine kinase inhibitor (TKI), is indicated for the treatment of adult patients (pts) with GIST who received prior treatment with 3 or more TKIs, including imatinib. We compared the efficacy and safety of ripretinib vs sunitinib in pts with advanced GIST who progressed on or were intolerant to imatinib. Methods: This multicenter, global, randomized, open-label phase 3 study (NCT03673501) enrolled adult pts with GIST who progressed on or had intolerance to imatinib. Pts were randomized 1:1 to ripretinib 150 mg once daily (QD) or sunitinib 50 mg QD (4 wks on/2 wks off). Randomization was stratified by KIT mutational status and imatinib intolerance. The primary endpoint was progression-free survival (PFS) by independent radiologic review (IRR) using modified RECIST version 1.1. Key secondary endpoints were objective response rate (ORR) by IRR and overall survival (OS). Hierarchical testing was performed for primary and key secondary endpoints in a prespecified sequence; testing pts with a KIT exon 11 primary mutation (Ex11 intention-to-treat [ITT] population) preceded the all-patient (AP) ITT population. Data cutoff was 1 Sep 2021; final analyses of PFS and ORR and the first interim analysis of OS were conducted. Results: A total of 453 pts were randomized to ripretinib (n = 226; Ex11 ITT, n = 163) or sunitinib (n = 227; Ex11 ITT, n = 164). Median age was 60 yrs (range 18–88) and most pts were white (66.2%) males (62.0%). PFS was not statistically different between ripretinib and sunitinib in the Ex11 ITT (hazard ratio [HR] 0.88, 95% CI 0.66, 1.16; P = 0.36; median 8.3 vs 7.0 mos) or in the AP populations (HR 1.05, 95% CI 0.82, 1.33; P = 0.72; median 8.0 vs 8.3 mos). ORR was numerically higher for ripretinib vs sunitinib in the Ex11 ITT (23.9% vs 14.6%; difference 9.3%, 95% CI 0.7, 17.8; nominal P = 0.03) and AP ITT populations (21.7% vs 17.6%; difference 4.2%, 95% CI −3.2, 11.5; nominal P = 0.27). OS data was highly immature; median OS was not reached in either arm. Fewer pts in the ripretinib arm experienced Grade 3-4 (G3-4) treatment-emergent adverse events (TEAEs) vs sunitinib (41.3% vs 65.6%). Among G3-4 TEAEs with a difference ≥5% between arms, ripretinib had fewer events vs sunitinib (hypertension [8.5% vs 26.7%], palmar-plantar erythrodysesthesia [1.3% vs 10.0%], neutropenia [0% vs 6.3%], and neutrophil count decreased [0% vs 7.2%]). Conclusions: The PFS in both arms was longer than PFS achieved by sunitinib in its pivotal phase 3 trial. While the PFS for ripretinib did not meet the primary endpoint of superiority vs sunitinib, meaningful clinical activity and fewer G3-4 TEAEs were observed in pts with advanced GIST treated with ripretinib after imatinib failure. Clinical trial information: NCT03673501.
Autologous CD34+ Stem Cell Therapy Increases Coronary Flow Reserve and Reduces Angina in Patients With Coronary Microvascular Dysfunction
Henry, Timothy D. , Merz, C. Noel Bairey , Wei, Janet , Corban, Michel T., Quesada, Odayme, Joung, Sandy , Kotynski, Christine L., Wang, Jian, Lewis, Michelle, Schumacher, Ann M., Bartel, Ronnda L., Takagi, Hiroshi, Shah, Vishal, Lee, Anna, Losordo, Douglas W., Bairey Merz, C Noel , Sietsema, William K , Lerman, Amir , Wei, Janet , Henry, Timothy D , Corban, Michel T., Quesada, Odayme, Joung, Sandy , Kotynski, Christine L., Wang, Jian, Lewis, Michelle, Schumacher, Ann M., Bartel, Ronnda L., Takagi, Hiroshi, Shah, Vishal, Lee, Anna, Losordo, Douglas W.

Mayo Clinic

Circulation: Cardiovascular Interventions | January 24, 2022 | Volume: 15 | Issue: 2 | Pages: No page available

10.1161/circinterventions.121.010802 | PMID 35067072 Get It

Background: Coronary microvascular dysfunction results in angina and adverse outcomes in patients with evidence of ischemia and nonobstructive coronary artery disease; however, no specific therapy exists. CD34+ cell therapy increases microvasculature in preclinical models and improves symptoms, exercise tolerance, and mortality in refractory angina patients with obstructive coronary artery disease. The objective of this research was to evaluate the safety, tolerability, and efficacy of intracoronary CD34+ cell therapy in patients with coronary microvascular dysfunction. Methods: We conducted a 2-center, 20-participant trial of autologous CD34+ cell therapy (protocol CLBS16-P01; NCT03508609) in patients with ischemia and nonobstructive coronary artery disease with persistent angina and coronary flow reserve ≤2.5. Efficacy measures included coronary flow reserve, angina frequency, Canadian Cardiovascular Society angina class, Seattle Angina Questionnaire, SF-36, and modified Bruce exercise treadmill test obtained at baseline and 6 months after treatment. Autologous CD34+ cells (CLBS16) were mobilized by administration of granulocyte-colony stimulating factor 5µg/kg/day for 5 days and collected by leukapheresis. Participants received a single intracoronary left anterior descending infusion of isolated CD34+ cells in medium that enhances cell function. Results: Coronary flow reserve improved from 2.08±0.32 at baseline to 2.68±0.79 at 6 months after treatment ( P <0.005). Angina frequency decreased ( P <0.004), Canadian Cardiovascular Society class improved ( P <0.001), and quality of life improved as assessed by the Seattle Angina Questionnaire ( P ≤0.03, all scales) and SF-36 ( P ≤0.04, all scales). There were no cell-related serious adverse events. Conclusions: In this pilot clinical trial of microvascular angina, patients with ischemia and nonobstructive coronary artery disease receiving intracoronary infusion of CD34+ cell therapy had higher coronary flow reserve, less severe angina, and better quality of life at 6 months. The current study supports a potential therapeutic role for CD34+ cells in patients with microvascular angina. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03508609.
Internet-based platform for a low-calorie dietary intervention involving prepackaged food for weight loss in overweight and obese individuals in China: protocol for a randomised controlled trial
Wang, Suyuan , Zhang, Chenghui , Zhong, Lingyu, Lerman, Lilach O. , Lerman, Amir , Guo, Yanhong , Wu, Yunhong , Wang, Suyuan , Lerman, Lilach O , Lerman, Amir , Wang, Xi , Zhong, Lingyu, López-Jiménez, Francisco

Mayo Clinic

BMJ Open | January 21, 2022 | Volume: 12 | Issue: 1 | Pages: e048106

10.1136/bmjopen-2020-048106 | PMID 35063952 Get It

Introduction Obesity is a global health issue that impacts quality of life. A calorie-restricted diet with high-intensity consultation provided via the internet may be an effective way to lose weight. The objective of this study was to assess the effectiveness of a practitioner-guided, mobile internet-based low-energy dietary intervention in overweight and obese populations in China. Methods and analysis This open-label randomised controlled trial enrolled 220 overweight and obese adults aged 18–70 years who met the inclusion criteria. Participants were assigned to the control group (n=110) or trial group (n=110). The trial group will be enrolled in the MetaWell programme, a weight loss programme using diet replacement products, wireless scales and a mobile phone app. Participants in the control group will receive paper material containing a sample diet for weight loss. The follow-up period will be 1 year, and measurements will occur at 3, 6 and 12 months. Dual-emission X-ray absorptiometry and abdominal quantitative CT will be performed to estimate the percentage of overall body fat and areas of visceral and subcutaneous fat, alongside several cardiometabolic measurements. The primary outcome of this study is the change in body mas index (BMI) at 6 months after enrolment. A mixed-effects model will be used to compare BMI and body fat changes between the two groups. Ethics and dissemination This study was approved by the ethics committee of the Hospital of Chengdu Office of the People’s Government of the Tibetan Autonomous Region. Advertisements for recruitment will be sent via official accounts using WeChat. The results will be disseminated via publications in academic journals and our clinic. Our study group will maintain contact with the participants to inform them of the study findings. Trial registration number ChiCTR1900021630.
Spray cryotherapy versus continued radiofrequency ablation in persistent Barrett’s esophagus
Genere, Juan Reyes , Visrodia, Kavel , Zakko, Liam , Hoefnagel, Sanne , Wang, Kenneth K, Hoefnagel, Sanne J M , Genere, Juan Reyes

Mayo Clinic

Diseases of the Esophagus | January 21, 2022 | Volume: 35 | Issue: 5 | Pages: No page available

10.1093/dote/doab084 | PMID 35059707 Get It

Abstract Radiofrequency ablation (RFA) is the first-line treatment for flat Barrett’s esophagus (BE) with dysplasia, however its role for persistent Barrett’s esophagus (PBE) is unclear. PBE requires additional RFA sessions or application of cryotherapy to improve therapeutic response. We performed a retrospective cohort study evaluating cases of PBE treated by endoscopic eradication programs, with and without spray cryotherapy, and evaluated their safety and efficacy. We retrospectively identified patients with PBE, defined as ≤50% BE reduction or unchanged dysplasia after at least two RFA sessions. PBE was treated either by continued RFA (RFA Group) or converting to spray cryotherapy (CRYO Group), both followed by surveillance period. The rate of adverse events (AE), complete response of intestinal metaplasia (CRIM) and complete response of dysplasia (CRD) were recorded. A total of 46 patients, 23 per group, underwent 622 endoscopic therapies. Circumferential BE length was longer in the CRYO Group, but other baseline characteristics were similar, including maximal BE length. Esophageal strictures accounted for 14/16 total AE, 71% of which were RFA related, compared with 14% related to spray cryotherapy (P = 0.02). Overall CRIM/CRD rates in CRYO (83%) and RFA (96%) groups were not statistically different (P = 0.16), however cases in the CRYO Group required more treatment encounters (Median 19 vs. 12, P ≤ 0.01). Multimodal endotherapy is effective for eradicating PBE. Treatment programs incorporating spray cryotherapy are associated with less esophageal strictures but may require more treatment sessions to achieve eradication.
Correction: An International Adult Guideline for Making Clozapine Titration Safer by Using Six Ancestry-Based Personalized Dosing Titrations, CRP, and Clozapine Levels
León, José de , Schoretsanitis, Georgios , Smith, Robert L. , Molden, Espen , Solismaa, Anssi , Seppälä, Niko , Kopeček, Miloslav , Švancer, Patrik , Olmos, I. Cánovas , Ricciardi, Carina , Iglesias-Alonso, Ana , Ruan, Can‐Jun , Wang, Chuanyue , Wang, Gang , Tang, Yi‐lang , Kim, Yong Sik , Kim, Se Hyun , Jung–Cook, Helgi , Nielsen, Jimmi , Verdoux, Hélène , Quilès, Clélia , Cohen, Dan , Schulte, Peter F.J. , Chopra, Nitin , McCollum, Betsy , Shelton, Charles , Cotes, Robert O. , Kaithi, Arun R., Farooq, Saeed , Ng, Chee H. , Bilbily, John , Lana, Fernando , Rădulescu, Flavian Ștefan , Seifritz, Erich , Every‐Palmer, Susanna , Bebawi, Emmanuel , Kelly, Deanna L. , Lazáry, Judit , Torres, Rafael , Yécora, Agustín, Berardis, Domenico De , Adebayo, Richard A. , Fountoulakis, Konstantinos Ν. , Ayub, Muhammad , Silva, Alzira , Bonelli, Raphael M., Crespo‐Facorro, Benedicto , Temmingh, Henk , Decloedt, Eric , Pedro, Maria Rosel , Gründer, Gerhard , Čelofiga, Andreja , Ristić, Dragana Ignjatović , Elkis, Hélio , Siskind, Dan , Masmoudi, R. , Saffian, Shamin Mohd , Buckley, P.F. , Freudenreich, Oliver , Müller, Daniel J. , de Leon, Jose , Olmos, Ismael , Iglesias-Garcia, Celso , Iglesias-Alonso, Ana , Spina, Edoardo , Ruan, Can-Jun , Wang, Chuan-Yue , Tang, Yi-Lang , Lin, Shih-Ku , Lane, Hsien-Yuan , Kim, Yong Sik , Kim, Se Hyun , Rajkumar, Anto P , González-Esquivel, Dinora F , Jung-Cook, Helgi , Baptista, Trino , Rohde, Christopher , Nielsen, Jimmi , Verdoux, Hélène , Quiles, Clelia , Sanz, Emilio J , De Las Cuevas, Carlos , Cohen, Dan , Schulte, Peter F J , Ertuğrul, Aygün , Anıl Yağcıoğlu, A Elif , Chopra, Nitin , McCollum, Betsy , Shelton, Charles , Cotes, Robert O , Kane, John M , Farooq, Saeed , Ng, Chee H , Bilbily, John , Hiemke, Christoph , López-Jaramillo, Carlos , McGrane, Ian , Lana, Fernando , Eap, Chin B , Every-Palmer, Susanna , Bousman, Chad A , Bebawi, Emmanuel , Bhattacharya, Rahul , Kelly, Deanna L , Otsuka, Yuji , Lazary, Judit , Motuca, Mariano , Chan, Sherry K W , Zolezzi, Monica , Ouanes, Sami , De Berardis, Domenico , Grover, Sandeep , Procyshyn, Ric M , Adebayo, Richard A , Kirilochev, Oleg O , Soloviev, Andrey , Fountoulakis, Konstantinos N , Wilkowska, Alina , Cubała, Wiesław J , Ayub, Muhammad , Silva, Alzira , Villagrán-Moreno, José M , Crespo-Facorro, Benedicto , Temmingh, Henk , Decloedt, Eric , Pedro, Maria R , Takeuchi, Hiroyoshi , Tsukahara, Masaru , Gründer, Gerhard , Sagud, Marina , Celofiga, Andreja , Ignjatovic Ristic, Dragana , Ortiz, Bruno B , Elkis, Helio , Pacheco Palha, António J , LLerena, Adrián , Fernandez-Egea, Emilio , Siskind, Dan , Weizman, Abraham , Masmoudi, Rim , Mohd Saffian, Shamin , Leung, Jonathan G , Buckley, Peter F , Marder, Stephen R , Citrome, Leslie , Freudenreich, Oliver , Correll, Christoph Ulrich , Müller, Daniel J , Kopecek, Miloslav , Schoretsanitis, Georgios , García, Celso Iglesias , Rajkumar, Anto P. , González‐Esquivel, Dinora F. , Rohde, Christopher , Sanz, Emílio J. , Cuevas, Carlos De las , Yağcıoğlu, A. Elif Anıl , Kane, John M. , Hiemke, Christoph , López‐Jaramillo, Carlos , McGrane, Ian R. , Arrojo, Manuel , Bousman, Chad , Bhattacharya, Rahul , Motuca, Mariano , Chan, Sherry Kit Wa , Кирилочев, О.О. , Soloviev, A. G. , Wilkowska, Alina , Cubała, Wiesław Jerzy , Tsukahara, Masaru , Ortiz, Bruno Bertolucci , LLerena, Adrián , Leung, Jonathan G. , Citrome, Leslie

Mayo Clinic

Pharmacopsychiatry | January 20, 2022 | Volume: 55 | Issue: 02 | Pages: e1-e1

10.1055/a-1737-1527 | PMID 35052001 Get It

Association of antibiotic treatment with immune-related adverse events in patients with cancer receiving immunotherapy
Jing, Ying , Chen, Xue , Chen, Xue, Li, Kunyan , Liu, Yaoming , Liu, Yuan , Lin, Steven H. , Diao, Lixia , Lou, Yanyan , Johnson, Douglas B. , Han, Leng , Lin, Steven H , Han, Leng , Chen, Xue, Zhang, Zhao , Chen, Yiqing , Wang, Yushu , Wang, Jing , Chen, Xiang , Liu, Hong

Mayo Clinic

Journal for ImmunoTherapy of Cancer | January 20, 2022 | Volume: 10 | Issue: 1 | Pages: e003779

10.1136/jitc-2021-003779 | PMID 35058327 Get It

Background To determine whether antibiotic treatment is a risk factor for immune-related adverse events (irAEs) across different patients with cancer receiving anti-PD-1/PD-L1 therapies. Methods The retrospective analysis includes clinical information from 767 patients with cancer treated at Hunan Cancer Hospital from 2017 to 2020. The pharmacovigilance data analysis includes individual cases of 38,705 safety reports from the US Food and Drug Administration Adverse Event Reporting System (FAERS) from 2014 to 2020, and 25,122 cases of safety reports from the World Health Organization database VigiBase from 2014 to 2019. All cases that received anti-PD-1/PD-L1 treatment were included. Multiomics data from patients across 25 cancer types were download from The Cancer Genome Atlas. Logistic regression and propensity score algorithm was employed to calculate OR of irAEs. Results Retrospective analysis of in-house patients showed that irAE potential risks are higher in all cancer (OR 2.12, 95% CI 1.38 to 3.22, false discovery rate (FDR) adjusted-p=1.93×10−3) and patients with lung cancer (OR 3.16, 95% CI 1.67 to 5.95, FDR adjusted-p=1.93×10−3) when using antibiotics. Potential risk of irAEs in patients with lung cancer with antibiotic treatment is significantly higher in FAERS (OR 1.39, 95% CI 1.21 to 1.59; FDR adjusted-p=1.62×10−5) and VigiBase (OR 1.32, 95% CI 1.09 to 1.59, FDR adjusted-p=0.05). Mechanistically, decreased microbial diversity caused by antibiotics use may increase the irAE risk through mediating the irAE-related factors. Conclusions Our study is the first to comprehensively demonstrate the associations of irAEs and antibiotic during anti-PD-1/PD-L1 therapy across a wide spectrum of cancers by analyzing multisource data. Administration of antibiotics should be carefully evaluated in patients with cancer treated by anti-PD-1/PD-L1 to avoid potentially increasing irAE risk.
Preclinical evaluation of LCK as a novel therapeutic target in YAP-activated and FGFR2-altered cholangiocarcinoma.
Buckarma, EeeLN H. , Werneburg, Nathan W., Watkins, Ryan , Guo, Yi , Wang, Juan , O’Brien, Daniel R. , Buijsman, Rogier C. , Vu, Diep, Man, Jos de , Truty, Mark J. , Conboy, Caitlin B. , Yonkus, Jennifer A. , Mun, Dong‐Gi , Vu, Diep, Ilyas, Sumera I. , Borad, Mitesh J. , Pandey, Akhilesh , Gores, Gregory J. , Smoot, Rory L.

Mayo Clinic

Journal of Clinical Oncology | January 19, 2022 | Volume: 40 | Issue: 4_suppl | Pages: 463-463

10.1200/jco.2022.40.4_suppl.463 Get It

463 Background: Molecularly targeted therapy is gaining traction in cholangiocarcinoma with the first FDA approval of a targeted agent in 2020, the FGFR inhibitor pemigatinib. Yet response rates and efficacy are modest, and most cholangiocarcinoma patients still lack targeted therapy options. The hippo pathway effector, YAP, is an oncogene that is activated in the majority of cholangiocarcinoma, yet attempts to develop YAP inhibitors have not yet been clinically successful. Recently, we described a novel mechanism of YAP regulation, via tyrosine phosphorylation by the Src-family kinase LCK. Therefore we hypothesized that LCK inhibition by may be therapeutic in cholangiocarcinoma through suppression of YAP activity. Methods: NTRC 0652-0 is a novel tyrosine kinase inhibitor with specificity for LCK. In vitro pharmacodynamics were defined. In cholangiocarcinoma cells, specificity for LCK inhibition was determined by mass spectrometry-based unbiased analysis of the tyrosine phosphoproteome following treatment with NTRC 0652-0 or genetic deletion of LCK. YAP phosphorylation and cotranscriptional activity, cell viability, and apoptosis were assessed. A panel of eight cholangiocarcinoma patient derived organoids (PDO) were characterized and tested for sensitivity to NTRC 0652-0. Two patient-derived xenograft (PDX) models bearing FGFR2-rearrangements were utilized for in vivo assessment of pharmacokinetics, toxicity, and efficacy. Results: NTRC 0652-0 demonstrated selectivity for LCK inhibition in vitro and in cholangiocarcinoma cells. NTRC 0652-0 treatment led to YAP inhibition and apoptotic cell death in cholangiocarcinoma cell lines, associated with inhibition of MCL1 expression. PDOs demonstrated variable sensitivity to NTRC 0652-0, correlated with basal YAP tyrosine phosphorylation and drug-induced suppression of YAP co-transcriptional activity. FGFR2-altered cholangiocarcinoma was also identified as a subset with enrichment of YAP target genes. Cells from an FGFR2-altered PDX were sensitive to NTRC 0652-0 despite being primarily resistant to pemigatinib. In two PDX models of FGFR2-altered cholangiocarcinoma, daily oral treatment with NTRC 0652-0 inhibited YAP tyrosine phosphorylation, and resulted in stable plasma and tumor drug levels, acceptable toxicity, and significantly decreased tumor growth. Conclusions: A novel LCK inhibitor, NTRC 0652-0, reduced YAP signaling and demonstrated preclinical efficacy in multiple patient-derived models of cholangiocarcinoma. LCK is a novel therapeutic target in cholangiocarcinoma, and YAP activation or FGFR2-alteration are potential biomarkers for response.